Excitement ran high last week – at the company, anyway – when Montreal-based Clementia Pharmaceuticals Inc. rolled out positive data from part B of its ongoing phase II trial testing palovarotene, a retinoic acid receptor gamma agonist, to treat the rare, life-threatening genetic bone disease called fibrodysplasia ossificans progressiva (FOP).